Top searches

PL

Resources

B2RLaw advises Proteon Pharmaceuticals on a strategic partnership with Skretting

01/02/2021

B2RLaw has advised Proteon Pharmaceuticals on a strategic partnership with Skretting aimed at providing functional solutions to tackle health challenges in the aquaculture industry.

The companies will collaborate on developing products using bacteriophage technology to support aquaculture farmers as part of a holistic health strategy. The companies will work in a parallel R&D pipeline on the project.

The Partnership allows Proteon to grow its product portfolio in aquaculture and expand its presence worldwide. Both Proteon Pharmaceuticals and Skretting predict that the technology will become a valuable component of integrated management strategies on-farm with both feed and water applications under investigation.

Proteon Pharmaceuticals is a Polish originating biotech company with a vision to develop natural feed additives that help remove antibiotics from the food chain and improve animal and human health. The Company uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics.

Norwegian company, Skretting is the world’s largest producer of feeds for farmed fish. The Company has operations on five continents and produces 2.5 million tonnes of feed annually, for more than sixty species of fish. Skretting has 3,500 employees worldwide. Skretting has an R&D unit known as Skretting Aquaculture Research Centre (ARC) with the main objective to provide research and technical support regarding fish and shrimp feed. It has 140 employees representing 25 nationalities.

B2RLaw’s team advising Proteon Pharmaceuticals was led by Partner George Havaris and included Counsels Paulina Wyrostek and Malwina Niczke – Chmura.

George Havaris advises, “Proteon Pharmaceuticals is a Polish company that is well on the path to being a global leader in its field of operation. Animal health is a little-known industry in the wider public eye. However, animal health is fundamental to the health and well-being of humans. We congratulate Proteon and Skretting on this exciting Partnership and we look forward to continuing our support to Proteon on its growth path”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

14/01/2022

B2RLaw advises Focus Estate Fund on the acquisition of Turawa Park shopping center

B2RLaw has advised real estate investment fund Focus Estate Fund on the acquisition of Turawa Park shopping center in Opole, […]

MORE
13/01/2022

B2RLaw advises on PLN 2 million investment into fintech company, Digital Gateways

B2RLaw has advised private investors on their PLN 2 million investment into fintech company Digital Gateways. Digital Gateways is a […]

MORE
30/12/2021

B2RLaw advises VC fund Meta Ventures on investment received by portfolio company Car Scanner

B2RLaw has advised Meta Ventures on portfolio company Car Scanner’s USD 2 million investment round. Meta Ventures, an early-stage venture […]

MORE
20/12/2021

B2RLaw advises Keyloop on its office lease to enter the Polish market

B2RLaw has advised Keyloop on its entry to the Polish market through the opening of its first office in Warsaw. […]

MORE
13/12/2021

B2RLaw advises InsurTech Gabi on Polish law aspects of its acquisition by Experian for USD 320 million

B2RLaw has advised InsurTech company Gabi on Polish law aspects of its acquisition by global information services company Experian for […]

MORE
17/11/2021

A Discussion on Venture Debt

For emerging companies, gaining access to financial resources can be a challenge. Traditional bank loans are often unavailable, and the […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close